Clinical Metabolomics & proteomics

Clinical Metabolomics & proteomics

We have developed and implemented mass spectrometry based methods for metabolomics and proteomics, including targeted and untargeted analyses of hormones, lipids and small signaling molecules in human CSF and in vitro cell cultures. We are currently involved in three large efforts; characterization and prediction of in vitro cell toxicity of exogenous substances (such as environmental contaminants and cancer drugs), better diagnostic markers for chronic pain states and early detection of Alzheimer’s disease. We are also part of the newly launched EU Horizon 2020 project “PhenoMeNal” with focus on implementing clinical metablomics into the clinic.